Prescription Drugs » Byetta

Exenatide and Sitagliptin Not Tied to Pancreatitis

admin — Fri, 10 Sep 2010 05:40:03 +0000

Neither exenatide (Byetta) nor sitagliptin (Januvia) causes acute pancreatitis, according to a pharmacy claims analysis. Reuters Health Information (Source: Medscape Diabetes Headlines)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Exenatide and Sitagliptin Not Tied to Pancreatitis is a post from: Prescription Drugs

Exenatide therapy in insulin-treated type 2 diabetes and obesity

admin — Fri, 20 Aug 2010 09:00:18 +0000

Conclusions: Exenatide therapy in insulin-treated type 2 diabetes and obesity was associated with very significant reductions in weight and insulin doses. Exenatide should be considered in people with type 2 diabetes on insulin and have obesity, weight gain and poor glycaemic control. (Source: QJM) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising. Exenatide therapy in insulin-treated type 2 diabetes and obesity is a post from: Prescription Drugs

Exenatide therapy in insulin-treated type 2 diabetes and obesity is a post from: Prescription Drugs

HTA: Newer agents for blood glucose control in type 2 diabetes

admin — Sun, 15 Aug 2010 05:40:03 +0000

This report aims to provide information on new drug developments to support a new drugs update to the 2008 guideline. It reviewed concerns about the safety of the thiazolidinediones as well as the following newer agents available for blood glucose control in type 2 diabetes:

. Glucagon-like peptide-1 (GLP-1) analogue exenatide . Dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin and vildagliptin . Long-acting insulin analogues glargine and detemir

The HTA concluded “Exenatide, the gliptins and detemir were all clinically effective. The long-acting insulin analogues glargine and detemir appeared to have only slight clinical advantages over NPH, but had much higher costs and did not appear to be cost-effective as first-line insulins for type 2 diabetes…

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

HTA: Newer agents for blood glucose control in type 2 diabetes is a post from: Prescription Drugs

The use of exenatide in severely burned pediatric patients

admin — Sun, 15 Aug 2010 05:40:02 +0000

Conclusions: Patients receiving exenatide received significantly lower amounts of exogenous insulin to control plasma glucose levels. Exenatide was well tolerated and potentially represents a novel agent to attenuate hyperglycemia in the critical care setting.Trial registration: NCT00673309. (Source: Critical Care) The use of exenatide in severely burned pediatric patients is a post from: Prescription Drugs

The use of exenatide in severely burned pediatric patients is a post from: Prescription Drugs

[Comment] Individualised incretin-based treatment for type 2 diabetes

admin — Tue, 10 Aug 2010 08:00:05 +0000

Type 2 diabetes is treated by a stepwise approach, starting with lifestyle changes at early stages (enforced by structured education for patients), combined with one or several glucose-lowering agents. Because of the progressive nature of the disease, an increasing number of glucose-lowering drugs have to be used with advancing diabetes duration. In The Lancet today, Richard Bergenstal and colleagues report the results of DURATION-2, comparing exenatide once weekly with either sitagliptin (an inhibitor of dipeptidyl peptidase-4) or pioglitazone (a thiazolidinedione), and Michaela Diamant and colleagues report the results of DURATION-3, comparing exenatide once weekly with insulin glargine titrated to predefined fasting glucose targets. Exenatide once weekly was superior for reduction of gl…

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

[Comment] Individualised incretin-based treatment for type 2 diabetes is a post from: Prescription Drugs

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

admin — Tue, 10 Aug 2010 08:00:04 +0000

Conclusion ischemic acute renal failure is supposed to be the consequence of the extracellular volume contraction caused by exenatide
(the result of continuous nausea and vomiting). This adverse effect could be caused by the co-administration of diuretics
and angiotensin II receptor antagonists.

Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11096-010-9423-8Authors
Alfonso López-Ruiz, Reina Sofía University Hospital Diabetes Unit 30003 Murcia SpainCristina del Peso-Gilsanz, Reina Sofía University Hospital Diabetes Unit 30003 Murcia SpainAmparo Meoro-Avilés, Reina Sofía University Hospital Diabetes Unit 30003 Murcia SpainJosé Soriano-Palao, Reina Sofía University Hospital Diabetes Unit 30003 Murcia SpainAlberto Andreu, Reina Sofía University Hospital Diabetes …

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers is a post from: Prescription Drugs

[Articles] Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

admin — Tue, 10 Aug 2010 08:00:04 +0000

Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin. (Source: LANCET) [Articles] Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial is a post from: Prescription Drugs

[Articles] Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial is a post from: Prescription Drugs

Retrospective analysis: Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin

admin — Tue, 10 Aug 2010 08:00:03 +0000

Source: Diabetes Care
Area: News
According to the results of an analysis published in Diabetes Care, there was no evidence that exenatide or sitagliptin increased the risk of acute pancreatitis. There was however an increased risk of AP seen in patients with diabetes compared to those without diabetes.

The authors performed a retrospective cohort study of a large medical and pharmacy claims database, and analysed data for 786,656 patients. The risk of AP for diabetic versus non-diabetic patients and for patients treated with exenatide and sitagliptin versus control diabetes medication were compared. The main findings were as follows:

. The incidence of AP was 1.91 cases per 1000 patient years in the non-diabetic control group, 5.6 in the diabet…

Retrospective analysis: Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin is a post from: Prescription Drugs

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

admin — Wed, 04 Aug 2010 12:20:03 +0000

Background:
Activation of glucagon-like peptide-1 (GLP-1) receptors improves insulin sensitivity and induces vasodilatation and diuresis. AC3174 is a peptide analogue with pharmacologic properties similar to the GLP-1 receptor agonist, exenatide. Hypothetically, chronic AC3174 treatment could attenuate salt-induced hypertension, cardiac morbidity, insulin resistance, and renal dysfunction in Dahl salt-sensitive (DSS) rats.
Methods:
DSS rats were fed low salt (LS, 0.3% NaCl) or high salt (HS, 8% NaCl) diets. HS rats were treated with vehicle, AC3174 (1.7 pmol/kg/min), or GLP-1 (25 pmol/kg/min) for 4 weeks via subcutaneous infusion. Other HS rats received captopril (150 mg/kg/day) or AC3174 plus captopril.
Results:
HS rat survival was improved by all treatments except GLP-1. Systolic blood p…

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats is a post from: Prescription Drugs

How Does Victoza Compare With Byetta?

admin — Wed, 04 Aug 2010 12:20:03 +0000

Should these GLP-1 receptor agonists for type 2 diabetes be considered the same? Medscape Pharmacists (Source: Medscape Today Headlines)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

How Does Victoza Compare With Byetta? is a post from: Prescription Drugs